Sample size/power for PD BE study 3-way crossover [Power / Sample Size]

posted by ElMaestro  – Denmark, 2011-04-01 19:14 (5561 d 09:15 ago) – Posting: # 6852
Views: 10,281

Hi jdetlor,

❝ I maybe missing something here, but from my understanding, we are not working with a linear ANOVA model in terms of a cross-over analysis, but with the Emax model and estimating the 'f' parameter or the bioavailability ...


yes, this isn't an lm.
Let's say your have an idea of variability within and between (i guess one could start out with gaussian variability but everything is possibly, especially since the FDA does not like parametrics for this analysis), and some guesses for ED50 and f etc. How do you incorporate the relevant variabilities to simulate the data?

Pass or fail!
ElMaestro

Complete thread:

UA Flag
Activity
 Admin contact
23,655 posts in 4,993 threads, 1,570 registered users;
117 visitors (0 registered, 117 guests [including 16 identified bots]).
Forum time: 04:29 CEST (Europe/Vienna)

Competence, like truth, beauty and contact lenses,
is in the eye of the beholder.    Laurence J. Peter

The Bioequivalence and Bioavailability Forum is hosted by
BEBAC Ing. Helmut Schütz
HTML5